One-year safety and efficacy of tobramycin powder for inhalation in patients with cystic fibrosis

Pediatr Pulmonol. 2016 Apr;51(4):372-8. doi: 10.1002/ppul.23358. Epub 2015 Dec 27.


This is an integrated analysis of data from patients with cystic fibrosis (CF) aged 6-21 years who were treated with up to seven cycles of tobramycin powder for inhalation (TIP(TM) ) over a period of at least 1 year. Safety and key efficacy endpoints were analyzed.

Results: The improvement in lung function and decrease in sputum P. aeruginosa (Pa) density from baseline were sustained over the 1-year treatment period. The number of adverse events (AEs) was low and did not increase with additional cycles of TIP treatment. Some increase in tobramycin minimum inhibitory concentration (MIC) was observed, but there was no significant increase in emergence of resistant strains based on the parenteral breakpoint for tobramycin.

Conclusion: Efficacy of TIP was maintained for up to seven cycles. Long-term treatment with TIP was generally safe and well tolerated with no increase in AEs.

Keywords: Cystic fibrosis; Pseudomonas aeruginosa; forced expiratory volume in one second; long-term safety; tobramycin powder for inhalation.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Inhalation
  • Adolescent
  • Anti-Bacterial Agents / therapeutic use*
  • Child
  • Cystic Fibrosis / complications*
  • Cystic Fibrosis / microbiology
  • Cystic Fibrosis / physiopathology
  • Double-Blind Method
  • Female
  • Humans
  • Male
  • Microbial Sensitivity Tests
  • Powders
  • Pseudomonas Infections / drug therapy*
  • Pseudomonas Infections / etiology
  • Pseudomonas aeruginosa / drug effects*
  • Sputum / drug effects*
  • Sputum / microbiology
  • Tobramycin / therapeutic use*
  • Treatment Outcome
  • Young Adult


  • Anti-Bacterial Agents
  • Powders
  • Tobramycin